Stool Gas Analysis: How VOCs Reveal Gut Microbiome Health

Feces smell for a reason. That aroma, unpleasant as it is, represents the metabolic output of trillions of bacterial cells communicating through chemistry. The volatile organic compounds responsible for it are precise molecular signatures of your gut microbiome's composition, metabolic activity and functional state. When Garner and colleagues applied solid-phase microextraction and GC-MS to stool from healthy donors and patients with gastrointestinal disease, they identified 297 distinct volatile compounds, of which 44 were shared by 80 percent of subjects, and found that volatile patterns from patients with ulcerative colitis, Clostridium difficile infection and Campylobacter jejuni infection each differed significantly from healthy donors (FASEB Journal, 2007).

This article covers the biochemistry, the analytical methodology and the clinical validation status of what researchers call the fecal volatilome.

The Volatilome: What Is Actually Being Measured

The volatilome is the complete spectrum of volatile organic compounds present in a biological sample. In stool, it comprises several hundred distinct chemical compounds, most of which are direct or indirect byproducts of bacterial fermentation, protein degradation and lipid metabolism. The Garner catalogue of 297 compounds, with a stable core of 44 present in most people, is the reference description of that space.

Volatility, in chemical terms, describes a substance's tendency to evaporate and exist as a gas at room or body temperature. These are not imprecise impressions of odor; they are measurable, reproducible chemical entities with defined molecular weights and structures. Hydrogen sulfide, with a molecular weight of 34 grams per mole, becomes perceptible to the human nose at concentrations well below one part per billion. Indole, a product of tryptophan fermentation with a molecular weight of 117 grams per mole, produces its characteristic odor at parts-per-million concentrations.

The relative concentrations of these compounds vary substantially with diet composition, microbiome structure, colonic transit time, medication history and disease state. That variability is not noise. It is signal. Roager and colleagues demonstrated the transit component directly, showing that colonic transit time is related to bacterial metabolism and mucosal turnover, with longer transit shifting metabolism from saccharolytic toward proteolytic as fermentable substrate runs out (Nature Microbiology, 2016).

Microbial Fermentation: The Biochemical Foundation

The human gut microbiome, dominated by members of the Bacteroidetes and Firmicutes phyla, survives on substrates that escape absorption in the small intestine: resistant starches, non-digestible carbohydrates, glycoproteins and amino acids. Breaking these down generates volatile organic compounds as unavoidable byproducts.

Take carbohydrate fermentation. When bacteria ferment glucose they generate pyruvate, which can then be metabolized along several routes: lactate production, acetyl-CoA generation, or further reduction to ethanol, acetaldehyde or acetone. Those latter compounds are volatile, so a community weighted toward particular fermentation strategies produces a correspondingly weighted volatile profile.

Short-chain fatty acids, particularly butyrate, propionate and acetate, are the metabolic outputs with the most direct physiological significance. Cummings and colleagues measured colonic contents and reported these three at roughly a 60:20:20 molar ratio, with total concentrations in the region of 100 millimoles per litre in the proximal colon, falling distally as substrate is consumed (Gut, 1987). Butyrate is produced primarily by bacteria such as Faecalibacterium prausnitzii and Roseburia species through the butyryl-CoA pathway.

Protein fermentation generates a distinct signature. When amino acids reach the colon, anaerobic bacteria cleave their side chains through Stickland reactions and related pathways. Tryptophan fermentation produces indole and indole derivatives, which are both volatile and biologically relevant (Roager and Licht, Nature Communications, 2018). Tyrosine and phenylalanine fermentation produce phenol, cresols and related compounds. Sulfur-containing amino acids such as methionine and cysteine are metabolized to hydrogen sulfide, dimethyl sulfide and dimethyl disulfide (Blachier et al., American Journal of Physiology-Gastrointestinal and Liver Physiology, 2021).

The core insight is that the volatilome is not incidental chemistry. It is a direct readout of which metabolic pathways currently dominate in your colon.

VOC Categories and Their Bacterial Sources

Class	Representative compounds	Precursor	Principal producers	Clinical significance
Sulfur compounds	Hydrogen sulfide, dimethyl sulfide, dimethyl disulfide, carbonyl sulfide	Dietary sulfate, cysteine, methionine	Desulfovibrio and other sulfate-reducing bacteria	Gasotransmitter at low concentration; mucus and barrier disruption at excess
Indolic compounds	Indole, skatole (3-methylindole), indole-3-propionate, indole-3-aldehyde	Tryptophan	Clostridium, Peptostreptococcus, Klebsiella pneumoniae, Escherichia coli	Aryl hydrocarbon receptor signalling and barrier support; indoxyl sulfate is a uremic toxin
Phenolic compounds	Phenol, p-cresol, cresolic isomers	Tyrosine, phenylalanine	Clostridium, Bacteroides	Absorbed and excreted as p-cresyl sulfate, a colon-derived uremic toxin
Aldehydes and ketones	Acetaldehyde, propionaldehyde, butyric aldehyde, acetone, 2-pentanone	Carbohydrate intermediates and lipid oxidation	Mixed fermentative community	Markers of active carbohydrate turnover
Branched-chain compounds	Iso-butyrate, iso-valerate, 3-methylbutanal	Branched-chain amino acids	Proteolytic Clostridium clusters	Indicator of protein fermentation dominance
Methane	Methane	Hydrogen and formate from bacterial fermentation	Methanobrevibacter smithii and other archaea	Associated with constipation and slower transit

Sulfur Compounds

Hydrogen sulfide, dimethyl sulfide, dimethyl disulfide and carbonyl sulfide dominate the foul-smelling aspects of stool gas. Blachier and colleagues review both routes of production, sulfate reduction and cysteine metabolism, and the consequences for the colonic and rectal mucosa. Research has associated elevated dimethyl sulfide with increased Desulfovibrio abundance and has implicated sulfur compounds in models of both IBS symptomatology and colorectal cancer risk, though mechanistic causality has not been definitively established.

Indolic Compounds

Indole, skatole (3-methylindole), indole-3-propionate and indole-3-aldehyde result from tryptophan fermentation. Their prevalence varies markedly with protein intake: higher-protein diets show elevated indolic volatiles, while plant-based higher-carbohydrate patterns show lower levels. Not all indole production is maladaptive. Indole itself acts as an aryl hydrocarbon receptor agonist with barrier-protective properties (Roager and Licht, 2018; Li et al., Frontiers in Pharmacology, 2021). Downstream, however, indoxyl sulfate and p-cresyl sulfate are among the best characterized colon-derived uremic toxins, accumulating in chronic kidney disease and associated with cardiovascular outcomes (Evenepoel et al., Kidney International, 2009).

Phenolic Compounds

Phenol, p-cresol and related cresolic isomers arise from tyrosine and phenylalanine fermentation. They are clinically interesting because they are absorbed, conjugated in the liver and excreted in urine, where they may serve as accessible biomarkers of protein fermentation patterns.

Aldehydes, Ketones and Esters

Acetaldehyde, propionaldehyde, butyric aldehyde and acetone result from carbohydrate fermentation and represent the volatile end-products of sugar metabolism. Ketones such as 2-pentanone may reflect lipid oxidation processes.

Branched-Chain Compounds

Iso-butyrate, iso-valerate and 3-methylbutanal result from branched-chain amino acid degradation, particularly when protein availability is high. Notably, 3-methylbutanoic acid was one of the two compounds in the best-performing colorectal cancer panel reported by Bond and colleagues, which is a useful reminder that putrefactive markers are not merely nuisance chemistry.

Methane

Methane is produced not by bacteria but by methanogenic archaea, principally Methanobrevibacter smithii, which consume hydrogen and formate generated by bacterial fermentation. Hoegenauer and colleagues review the consistent association between methane production and constipation, and with constipation-predominant rather than diarrhea-predominant irritable bowel syndrome (Nature Reviews Gastroenterology & Hepatology, 2022).

Analytical Methodology

Platform	What it produces	Sensitivity	Speed	Main limitation
GC-MS with headspace SPME or thermal desorption	Identified compounds with quantitation	Down to parts per trillion for some analytes	Tens of minutes to hours per sample	Laboratory infrastructure and trained operators
SIFT-MS	Real-time concentrations of targeted compounds	Parts per billion	Seconds to minutes	No chromatographic separation, so isomers are indistinguishable
PTR-MS	Real-time proton-transfer ionization spectra	Parts per trillion to parts per billion	Seconds	Limited structural resolution relative to GC-MS
GC-IMS	Two-dimensional retention and drift-time patterns	Parts per billion	Minutes	Compound identification depends on reference libraries
Electronic nose sensor arrays	A composite pattern, not molecular identities	Compound and sensor dependent	Seconds to minutes	Pattern only; requires GC-MS to interpret what drives a classification

Gas Chromatography-Mass Spectrometry

GC-MS remains the reference standard for fecal volatilome characterization. The workflow involves headspace sampling, thermal desorption or solid-phase microextraction of volatile compounds, separation by capillary gas chromatography and identification by mass spectrometry. De Preter and colleagues developed one of the standard on-line purge-and-trap GC-MS screening methods for fermentation metabolites in fecal samples, which is the kind of methodological work the field depends on (Journal of Chromatography A, 2009).

Sample handling is a critical methodological consideration. Volatile compounds begin degrading immediately upon collection, and temperature, oxygen exposure and storage duration all substantially affect the profile detected. This standardization challenge is one of the main obstacles to making VOC analysis a reproducible clinical test.

Real-Time Mass Spectrometry Methods

Selected ion flow tube mass spectrometry (SIFT-MS) offers real-time direct analysis without chromatographic separation, using a flowing afterglow of ions to ionize volatiles which are then mass-selected and detected. It can produce results in seconds to minutes, at the cost of reduced specificity: isomers cannot be distinguished. Proton transfer reaction mass spectrometry (PTR-MS) works on a similar principle and offers comparable speed with less chromatographic resolution than GC-MS.

Electronic Noses and Sensor Arrays

Electronic nose systems use arrays of chemical sensors, each with a different selectivity profile, to generate a composite electrical pattern characteristic of a given gas mixture. Machine learning algorithms can classify these patterns without identifying specific compounds. A 2024 review in the Journal of Cancer Research and Clinical Oncology surveys their application across gastrointestinal disease and notes that reported discrimination frequently sits in the 0.8 to 0.9 AUROC range while cross-study reproducibility remains the weak point (Ma et al., 2024). The disadvantage is that the output is a chemical pattern rather than a set of molecular structures, so understanding which compounds drive a given classification requires supporting GC-MS work.

The precedent for sensor-array diagnostics is older than the gut literature. Machado and colleagues showed in 2005 that a sensor array analysis of exhaled breath could distinguish lung cancer patients from controls, which established the pattern-recognition principle now being applied to stool (American Journal of Respiratory and Critical Care Medicine, 2005).

The Fecal Volatilome and Disease

The clinical relevance of VOC analysis rests on evidence that disease states produce characteristic, reproducible volatilome signatures. Most of this evidence remains at the research stage, but it is now quantified well enough to summarize.

Inflammatory Bowel Disease

The strongest synthesis is a 2024 systematic review and meta-analysis in the Journal of Crohn's and Colitis. Krishnamoorthy and colleagues reviewed 16 studies and meta-analyzed 10, covering 696 inflammatory bowel disease cases against 605 controls, and reported pooled sensitivity of 87 percent (95 percent CI 0.79 to 0.92), pooled specificity of 83 percent (95 percent CI 0.73 to 0.90), and an area under the curve of 0.92.

Individual studies show what sits behind that pooled figure. Walton and colleagues analyzed volatile organic compounds of bacterial origin across chronic gastrointestinal diseases and found distinguishable profiles between conditions (Inflammatory Bowel Diseases, 2013). Arasaradnam and colleagues, studying 48 patients with inflammatory bowel disease and 14 healthy controls with electronic nose and field asymmetric ion mobility spectrometry, reported 75 percent accuracy separating disease from controls, and sensitivity and specificity of 67 percent each when attempting to separate ulcerative colitis from Crohn's disease (Inflammatory Bowel Diseases, 2013). The gap between 87 percent pooled and 67 percent for subtype discrimination is the honest state of the field.

The proposed mechanism relates to altered community composition: sulfate-reducing bacteria proliferate in inflamed colons, and populations fermenting sulfur compounds increase in response to mucus degradation and altered permeability.

Colorectal Cancer

Colorectal cancer research has produced some of the more striking distinctions. Bond and colleagues analyzed fecal headspace from 137 participants, comprising 60 with no neoplasia, 56 with adenomatous polyps and 21 with adenocarcinoma. Propan-2-ol alone was significantly more abundant in cancer samples with an AUROC of 0.76. Combined with 3-methylbutanoic acid the AUROC rose to 0.82, with sensitivity 87.9 percent and specificity 84.6 percent. A separate three-compound presence-or-absence panel of propan-2-ol, hexan-2-one and ethyl 3-methyl-butanoate gave an AUROC of 0.73, with the presence of all three associated with roughly a sixfold higher likelihood of cancer (Alimentary Pharmacology & Therapeutics, 2019).

Urine carries a related signal. Arasaradnam and colleagues showed that urinary VOC analysis could also discriminate colorectal cancer from controls (PLoS ONE, 2014), and Daulton and colleagues extended the approach to pancreatic cancer detection from urine (Talanta, 2021). Proposed mechanisms involve altered microbial communities near tumors, increased proteolytic metabolism from blood and necrotic tissue, and altered fermentation.

Irritable Bowel Syndrome and Bile Acid Diarrhoea

IBS presents a distinct challenge for biomarker discovery because it is defined by symptoms rather than established pathophysiology. Ahmed and colleagues nonetheless identified fecal volatile organic metabolites that separated IBS patients from healthy controls (PLoS ONE, 2013).

Bile acid diarrhoea is a more tractable target because it is a defined entity with a specific treatment. Covington and colleagues applied a sensor-based volatile analysis tool to bile acid diarrhoea and reported that it could distinguish affected patients, which is a clinically actionable distinction that stool appearance alone cannot make (Sensors, 2013).

Clostridioides difficile Infection

Active C. difficile infection produces a recognizable volatilome signature, reflecting both the pathogen's own metabolic output and the associated dysbiosis. This was visible in the original Garner series, where C. difficile samples differed significantly from healthy donors. The wider infectious disease application is reviewed in Clinical Microbiology Reviews (Sethi et al., 2013).

Diet, Microbiome Dynamics and the Changing Volatilome

One of the more elegant applications of VOC analysis is tracking how dietary change reshapes metabolic output. Research suggests that volatilome shifts occur within a few days of dietary intervention, often preceding compositional shifts detectable by sequencing.

When someone transitions to a high-fiber plant-based diet, carbohydrate-fermenting bacteria including Roseburia, Faecalibacterium and Prevotella species expand, and the volatile profile shifts toward increased short-chain volatile compounds with reduced indolic and phenolic content. This is the same direction Roager and colleagues observed with faster transit: less time for substrate exhaustion means fermentation stays saccharolytic.

High-protein, lower-carbohydrate patterns produce the opposite movement, with increases in indolic and phenolic volatiles within days as tryptophan and tyrosine fermentation intensifies.

Probiotic interventions show measurable but variable effects. Antibiotic therapy produces dramatic volatilome suppression, as expected, and the reconstruction phase shows interesting dynamics, since the first species to recolonize produce their characteristic signatures. For the wider research context, see our overview of gut microbiome science and VOC analysis.

Hypothetical scenario. As an illustrative scenario, imagine someone whose fecal volatile profile shows high dimethyl sulfide and iso-valerate alongside low short-chain fatty acid derived compounds, on a habitual diet high in animal protein and low in fiber. Following the chemistry described above, increasing fermentable fiber would be expected to move that profile toward short-chain fatty acid compounds and away from sulfur and branched-chain markers, with the change appearing within days rather than months. This is a constructed illustration of the published mechanism. It is not a real person, not a SNIFR result, and not a clinical recommendation.

Standardization and Reproducibility

Despite compelling science, VOC analysis remains limited in clinical adoption because of standardization challenges. Different laboratories analyzing the same stool sample can obtain substantially different profiles depending on:

• Sample collection method, including immediate freezing versus room temperature storage.
• Time between collection and analysis, since volatiles degrade while residual microbial metabolism produces new ones.
• Headspace equilibration temperature and duration.
• Gas chromatography column chemistry and flow rates.
• Mass spectrometry tuning parameters.
• Data processing and peak identification methodology.

These are not trivial variables. This is also why the Krishnamoorthy meta-analysis had to pool across quite different platforms, and why its pooled confidence intervals are as wide as they are. Addressing it requires standardized collection and processing protocols, cross-laboratory validation studies, reference materials with known volatile profiles, and harmonized data analysis pipelines.

From Volatiles to Functional Health

The volatilome connects to metabolomics more broadly. The fecal metabolome includes thousands of compounds, of which the volatile subset is the fraction measurable non-invasively. The advantage of focusing on volatiles for at-home monitoring is practical: they can be measured from headspace without specimen preparation, shipping or laboratory infrastructure. Research has also demonstrated that GC-MS analysis of fecal volatiles can discriminate gastrointestinal disease states from healthy controls in screening contexts (Dalis et al., Microorganisms, 2023).

SNIFR's Approach to Passive At-Home Monitoring

Traditional microbiome testing provides a snapshot. But the microbiome is dynamic, and the volatilome changes in response to meals, activity, stress, infection and circadian rhythm.

The hypothesis behind SNIFR's technology is that frequent sampling of the volatile profile provides a dynamic readout revealing patterns a single snapshot cannot. The approach enables passive at-home VOC measurement, sampling in the home environment rather than requiring samples to be collected, packaged and shipped.

The intended advantages are several: temporal resolution, no biospecimen shipping and therefore fewer degradation artifacts, accessibility, and the accumulation of longitudinal data that could support models recognizing personal baselines. The technical challenge is genuinely substantial. SNIFR's technology is currently in development and has not been clinically validated. Flare-up prediction and early warning are design goals for the product, not demonstrated capabilities, and the platform is not designed to detect, diagnose or predict any disease.

What Clinical Validation Actually Requires

Publishing research showing that a VOC biomarker discriminates disease from health is not the same as clinical validation. Genuine validation requires:

• Large prospective multi-center studies with clearly defined case and control groups. The largest fecal VOC studies to date involve one to a few hundred participants each.
• Pre-specified analysis plans. In high-dimensional data with hundreds of compounds, post hoc analyses will find statistically significant associations almost by construction.
• External validation. A model trained on one population must hold up in an independent population with different demographics, geography and dietary patterns.
• Demonstrated clinical utility. A test must provide information that changes management.
• Cost-effectiveness analysis relative to existing diagnostic approaches.

These requirements are why translating academic research into clinical tests takes years. The tedium is the point; it is what separates validated diagnostics from unvalidated speculation.

Personalized Baselines and Predictive Analytics

As volatile monitoring becomes more feasible, the more useful interpretive frame is an individual's personal baseline rather than a population norm. A particular sulfide concentration might be entirely normal for one person and notable for another. Population-level thresholds carry less information than individual trajectories.

Predictive analytics is the next frontier and remains speculative. If long volatilome trajectories exist for large numbers of individuals, it may become possible to identify patterns that precede clinical events. Answering that requires large prospective datasets and rigorous validation, since spurious patterns are easy to find in complex data.

What We Do Not Know

• Most VOC-disease associations are observational, and clear causal mechanisms are not established.
• The volatilome is highly sensitive to pre-analytical factors that may not be fully characterized.
• Individual variation is large. Some people show stable volatilome signatures while others vary markedly day to day for reasons not currently understood.
• Subtype discrimination is much weaker than case-control discrimination. Separating inflammatory bowel disease from health reaches pooled sensitivity of 87 percent; separating ulcerative colitis from Crohn's disease has been reported at 67 percent.
• The clinical utility of volatilome monitoring for most conditions remains speculative.

This is not pessimism. It is appropriate caution. The field is genuinely promising and moving toward practical application, but it has not arrived.

The Molecular Conversation Beneath the Surface

The gut microbiome is a community of metabolically active organisms communicating through chemistry. The volatile compounds they produce are direct readouts of dominant metabolic pathways and of the functional state of the ecosystem. Stool gas that seems merely unpleasant is, in reality, a sophisticated chemical signal.

As technologies mature and validation studies accumulate, VOC analysis has a plausible future as a standard component of gut health assessment, not as a replacement for sequencing but as a complementary measurement focused on metabolic function rather than composition alone.

Frequently Asked Questions

Why does stool smell, and what does the smell actually indicate?

Stool odor comes from volatile compounds produced by bacterial metabolism, principally sulfur compounds, indoles and phenolics generated when bacteria ferment amino acids. Garner and colleagues catalogued 297 such compounds in human fecal headspace, 44 of them present in 80 percent of subjects. The proportions shift with diet and microbial composition, which is why odor carries genuine information.

What is the fecal volatilome?

The fecal volatilome is the complete set of volatile organic compounds present in a stool sample, typically several hundred distinct chemical species. Most are direct or indirect byproducts of bacterial fermentation, protein degradation and lipid metabolism. Their relative concentrations vary with diet, microbiome structure, colonic transit time and disease state.

How is stool gas analysis performed in a laboratory?

The reference approach is headspace sampling followed by gas chromatography-mass spectrometry. Stool is sealed in a vial so volatiles equilibrate into the gas phase, those compounds are extracted and concentrated by solid-phase microextraction or thermal desorption, separated by capillary gas chromatography, then identified by mass spectrometry. For some analytes it reaches parts-per-trillion sensitivity.

What is an electronic nose and how does it differ from GC-MS?

An electronic nose uses an array of chemical sensors with different selectivity profiles to generate a composite pattern characteristic of a gas mixture. It is fast, small and inexpensive, but it produces patterns rather than molecular identifications. The principle was established in breath analysis, where a sensor array distinguished lung cancer patients from controls as early as 2005.

How accurate is stool VOC analysis for inflammatory bowel disease?

A 2024 meta-analysis pooling 10 studies with 696 cases and 605 controls reported sensitivity 87 percent, specificity 83 percent and an area under the curve of 0.92 for separating inflammatory bowel disease from controls. Separating ulcerative colitis from Crohn's disease is much harder, with one study reporting 67 percent sensitivity and 67 percent specificity for that task.

How quickly does diet change stool volatile compounds?

Research suggests meaningful shifts in volatile profiles occur within a few days of a substantial dietary change, often before compositional changes become obvious in sequencing data. Moving toward high-fiber plant-based eating tends to shift the profile toward short-chain volatile compounds. Higher-protein eating tends to increase indolic and phenolic compounds.

Is VOC analysis a validated clinical test yet?

No. Fecal VOC analysis remains a research method rather than an approved clinical diagnostic. The main obstacle is standardization, since collection method, storage time, temperature and analytical parameters all substantially affect results. Large prospective multi-center validation with pre-specified analysis plans is what the field still needs.

References

• Garner CE, Smith S, de Lacy Costello B, et al. Volatile organic compounds from feces and their potential for diagnosis of gastrointestinal disease. The FASEB Journal. 2007;21(8):1675-1688. doi:10.1096/fj.06-6927com
• Ahmed I, Greenwood R, de Lacy Costello B, et al. An investigation of fecal volatile organic metabolites in irritable bowel syndrome. PLoS ONE. 2013;8(3):e58204. doi:10.1371/journal.pone.0058204
• Walton C, Fowler DP, Turner C, et al. Analysis of volatile organic compounds of bacterial origin in chronic gastrointestinal diseases. Inflammatory Bowel Diseases. 2013;19(10):2069-2078. doi:10.1097/MIB.0b013e31829a91f6
• Arasaradnam RP, Ouaret N, Thomas MG, et al. A Novel Tool for Noninvasive Diagnosis and Tracking of Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2013;19(5):999-1003. doi:10.1097/MIB.0b013e3182802b26
• Arasaradnam RP, McFarlane MJ, Ryan-Fisher C, et al. Detection of Colorectal Cancer (CRC) by Urinary Volatile Organic Compound Analysis. PLoS ONE. 2014;9(9):e108750. doi:10.1371/journal.pone.0108750
• Bond A, Greenwood R, Lewis S, et al. Volatile organic compounds emitted from faeces as a biomarker for colorectal cancer. Alimentary Pharmacology & Therapeutics. 2019;49(8):1005-1012. doi:10.1111/apt.15140
• Krishnamoorthy A, Chandrapalan S, Ahmed M, et al. The diagnostic utility of volatile organic compounds in inflammatory bowel disease: a systematic review and meta-analysis. Journal of Crohn's and Colitis. 2024;18(2):320-330. doi:10.1093/ecco-jcc/jjad132
• Covington JA, Westenbrink EW, Ouaret N, et al. Application of a novel tool for diagnosing bile acid diarrhoea. Sensors. 2013;13(9):11899-11912. doi:10.3390/s130911899
• De Preter V, Van Staeyen G, Esser D, et al. Development of a screening method to determine the pattern of fermentation metabolites in faecal samples using on-line purge-and-trap gas chromatographic-mass spectrometric analysis. Journal of Chromatography A. 2009;1216(9):1476-1483. doi:10.1016/j.chroma.2008.12.095
• Daulton E, Wicaksono AN, Tiele A, et al. Volatile organic compounds (VOCs) for the non-invasive detection of pancreatic cancer from urine. Talanta. 2021;221:121604. doi:10.1016/j.talanta.2020.121604
• Machado RF, Laskowski D, Deffenderfer O, et al. Detection of Lung Cancer by Sensor Array Analyses of Exhaled Breath. American Journal of Respiratory and Critical Care Medicine. 2005;171(11):1286-1291. doi:10.1164/rccm.200409-1184OC
• Sethi S, Nanda R, Chakraborty T. Clinical Application of Volatile Organic Compound Analysis for Detecting Infectious Diseases. Clinical Microbiology Reviews. 2013;26(3):462-475. doi:10.1128/cmr.00020-13
• Ma T, Chang Z, Zhang N, et al. Application of electronic nose technology in the diagnosis of gastrointestinal diseases: a review. Journal of Cancer Research and Clinical Oncology. 2024;150(8):390. doi:10.1007/s00432-024-05925-w
• Blachier F, Andriamihaja M, Larraufie P, et al. Production of hydrogen sulfide by the intestinal microbiota and epithelial cells and consequences for the colonic and rectal mucosa. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2021;320(2):G125-G135. doi:10.1152/ajpgi.00261.2020
• Roager HM, Licht TR. Microbial tryptophan catabolites in health and disease. Nature Communications. 2018;9(1):3294. doi:10.1038/s41467-018-05470-4
• Li X, Zhang B, Hu Y, et al. New insights into gut-bacteria-derived indole and its derivatives in intestinal and liver diseases. Frontiers in Pharmacology. 2021;12:769501. doi:10.3389/fphar.2021.769501
• Hoegenauer C, Hammer HF, Mahnert A, et al. Methanogenic archaea in the human gastrointestinal tract. Nature Reviews Gastroenterology & Hepatology. 2022;19(12):805-813. doi:10.1038/s41575-022-00673-z
• Evenepoel P, Meijers BKI, Bammens BRM, et al. Uremic toxins originating from colonic microbial metabolism. Kidney International. 2009;76(Suppl 114):S12-S19. doi:10.1038/ki.2009.402
• Cummings JH, Pomare EW, Branch WJ, et al. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut. 1987;28(10):1221-1227. doi:10.1136/gut.28.10.1221
• Dalis C, Mesfin FM, Manohar K, et al. Volatile Organic Compound Assessment as a Screening Tool for Early Detection of Gastrointestinal Diseases. Microorganisms. 2023;11(7):1822. doi:10.3390/microorganisms11071822
• Roager HM, Hansen LBS, Bahl MI, et al. Colonic transit time is related to bacterial metabolism and mucosal turnover in the gut. Nature Microbiology. 2016;1(9):16093. doi:10.1038/nmicrobiol.2016.93

SNIFR is designed to provide insights about gut health patterns, not to diagnose or treat medical conditions. Individual results may vary as gut health is influenced by numerous factors including diet, stress, sleep, and genetics. SNIFR is currently in development, and features described may evolve before commercial release.